axitinib + avelumab + bavituximab

This is a **combination investigational therapy** consisting of three active agents: axitinib, avelumab, and bavituximab. - **Axitinib** is a small molecule tyrosine kinase inhibitor (VEGFR1, VEGFR2, VEGFR3) used as an antiangiogenic agent in cancer therapy. - **Avelumab** is a human monoclonal antibody that targets PD-L1, acting as an immune checkpoint inhibitor to enhance anti-tumor immune response. - **Bavituximab** is a chimeric monoclonal antibody that targets phosphatidylserine, a marker exposed on the tumor vasculature, aiming to modulate the immune response and disrupt the tumor microenvironment. This triple combination is being investigated for enhanced anti-tumor effects, notably in **advanced solid tumors**. The rationale is that antiangiogenic therapy (axitinib) can normalize tumor vasculature and modulate the tumor microenvironment to improve immune cell infiltration, while immune checkpoint inhibition (avelumab) and modulation of immune activity via phosphatidylserine blockade (bavituximab) may have additive or synergistic antineoplastic effects. Phase I/II trials are ongoing or have been conducted for combinations of axitinib + avelumab, but the specific triplet with bavituximab is experimental and under clinical investigation[5].